Arcellx: Partial Clinical Hold Lifted By FDA On IMMagine-1 Phase 2 Trial; Q2 Net Loss Narrows

Arcellx, Inc. (ACLX), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on its CART-ddBCMA investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma or rrMM.

Related Keywords

United States , ,Arcellx Inc ,More Such Health News ,Drug Administration ,Kite Pharma Inc ,Nasdaq ,Clinical Program ,Kite Pharma ,Chief Executive Officer ,Fda ,Multiple Myeloma ,Clinical Hold ,Partial Clinical Hold ,Rrmm ,Arcellx ,Rcellx Immagine 1 ,Art Ddbcma ,